Talent Pool

Contributed by:

PharmaVOICE Staff

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Biopharma pool

PV0416_RowenaChoudrieRowena Choudrie
Kevin Zikaras
Actinium Pharmaceuticals Adds to Product Development and Clinical Research Teams
Actinium Pharmaceuticals, a biopharmaceutical company developing innovative, targeted payload immunotherapeutics for the treatment of advanced cancers, has appointed Rowena Choudrie to the position of senior director, pharmaceutical product development, and Kevin Zikaras to the position of senior clinical scientist.

Ms. Choudrie has more than 20 years of pharmaceutical industry experience with roles of increasing responsibility in product development. At Actinium, she is responsible for clinical trial material supply, drug product process scale-up to support commercial supply and final product formulation.

Mr. Zikaras joins Actinium from Bristol-Myers Squibb, where he was a clinical protocol manager in the immuno-oncology group since 2014.

PV0416_DrPaulKessnerDrDavidWustrowDr. Paul Kassner
Dr. David Wustrow
FLX Bio Hires Senior Leaders in
Immuno-Oncology Drug Discovery
FLX Bio, a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, has appointed Paul Kassner, Ph.D., as VP, quantitative biology, and David Wustrow, Ph.D., as VP, drug discovery.

Dr. Kassner joined FLX Bio after 18 years of building and leading high-performance technical groups in various biopharmaceutical organizations. Most recently, he was director of research and head of the genome analysis unit at Amgen.

Before joining FLX Bio, Dr. Wustrow held the position of VP, chemical and pharmaceutical sciences at Cleave Biosciences.

Gary Zieziula
PV0416_GaryZieziulaEMD Serono Appoints President and Managing Director
EMD Serono, the North America biopharma business of Merck KGaA, Darmstadt, Germany, has appointed Gary Zieziula president and managing director, North America. In this role, he is responsible for all areas of the company’s business, including driving overall strategic direction and maximizing growth across the region. Mr. Zieziula joined EMD Serono in 2014 as chief commercial officer, responsible for the performance of the company’s franchises in multiple sclerosis, fertility, endocrinology, and oncology.

EMD Serono is a leader in specialty care, integrating cutting-edge science, innovative medicines and devices, as well as industry-leading patient support and access programs.

CRO Pool

PV0416_JulieRossJulie Ross
Advanced Clinical Appoints President
Advanced Clinical, a clinical development organization, has promoted Julie Ross to president.

Ms. Ross’ broadened span of responsibilities include leading all of the business lines within Advanced Clinical, inclusive of CRO, strategic talent acquisition, FSP, quality services, and computer systems validation.

She is on the board of directors for the Healthcare Businesswomen’s Association.

Agency Pool

PV0416_LaurieBartolomeoDrewDesjardinsLaurie Bartolomeo
Drew Desjardins
John Kemble
Dr. Dan Zaksas
Dudnyk Makes Promotions
Laurie Bartolomeo, Drew Desjardins, and John Kemble have been promoted from senior VPs at Dudnyk to executive VPs. In addition, Dan Zaksas, Ph.D., has been promoted to senior VP, director of medical and scientific affairs.

The collaboration between Ms. Bartolomeo, executive VP, creative director, and Mr. Kemble, executive VP, creative PV0416_JohnKembleDrDanZaksasdirector, began in 2006 with Ms. Bartolomeo’s return to Dudnyk after a four-year hiatus. Their early partnership produced award-winning work for many of Dudnyk’s clients.

Mr. Desjardins, executive VP, chief strategy officer, joined the Dudnyk team in 2011 to provide strategy guidance to the agency’s clients and business development activities.

Dr. Zaksas, senior VP, director of medical and scientific affairs, provides scientific guidance and medical strategy across the full spectrum of products and therapeutic areas at Dudnyk.

PV0416_BurcinJamisonYoungDoug Burcin
Leslie Jamison
Michael Young
Klick Hires Three Senior Executives
Doug Burcin has joined Klick as chief growth officer. Leslie Jamison is Klick’s new senior VP of brand strategy. And Michael Young is VP of strategy at Klick’s Sensei Labs.

Mr. Burcin is focused on expanding Klick’s capabilities. He joins Klick after spending 17 years at Havas Health, the last eight as global CEO.

Ms. Jamison brings more than 25 years of experience in brand strategy development, and customer insight-driven marketing to Klick.
Previously, she was managing director at in-sync, focused on healthcare.

PV0416_TammyFischerMr. Young was formerly VP, business development for Parexel International.

Tammy Fischer
McCann Health Appoints Chief Growth Officer for North America
McCann Health has appointed Tammy Fischer to the new role of executive VP, chief growth officer, for McCann Health North America. Ms. Fischer has more than two decades of healthcare expertise. She was president of GSW Worldwide New York.(PV)

Posted in:

Post a Comment

You must be logged in to post a Comment.